Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
NCT00161668 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2007-03-15
Summary
This study is designed to assess the safety of Mylotarg therapy in routine practice.
Conditions
Interventions
- DRUG
-
Mylotarg
Sponsors & Collaborators
-
Wyeth is now a wholly owned subsidiary of Pfizer
lead INDUSTRY
Principal Investigators
-
Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-10-31
Countries
- United States
Study Locations
More Related Trials
-
Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment
NCT01698879 ·Status: COMPLETED ·Phase: PHASE2
-
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
NCT00085709 ·Status: COMPLETED ·Phase: PHASE3
-
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
NCT02221310 ·Status: COMPLETED ·Phase: PHASE2
-
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
NCT00766116 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS
NCT00195000 ·Status: COMPLETED ·Phase: PHASE2
-
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
NCT00049179 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
NCT00037596 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarkers in DNA Samples From Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin
NCT01139320 ·Status: COMPLETED
-
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
NCT00006122 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia
NCT00304447 ·Status: COMPLETED ·Phase: PHASE4
-
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00372593 ·Status: COMPLETED ·Phase: PHASE3
-
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
NCT03531918 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation
NCT00460447 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00006265 ·Status: COMPLETED ·Phase: PHASE2
-
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
NCT02312037 ·Status: NO_LONGER_AVAILABLE
-
Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
NCT03727750 ·Status: COMPLETED ·Phase: PHASE4
-
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT00091234 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia
NCT00037583 ·Status: COMPLETED ·Phase: PHASE2
-
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT04659616 ·Status: RECRUITING ·Phase: PHASE1
-
Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®
NCT03287128 ·Status: UNKNOWN
-
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
NCT00038805 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
NCT00927498 ·Status: COMPLETED ·Phase: PHASE3
-
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT00658814 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation
NCT00893399 ·Status: COMPLETED ·Phase: PHASE3
-
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
NCT03737955 ·Status: RECRUITING ·Phase: PHASE2